Wealth Enhancement Advisory Services increased its Bitcoin ETF holdings from $22 million to $33 million in the second quarter of 2026, diversifying across several funds including Fidelity Wise Origin Bitcoin Fund, ARK 21Shares Bitcoin ETF, and VanEck Bitcoin ETF. While its stake in the Fidelity fund decreased, overall Bitcoin ETF exposure grew, reflecting varied client needs and issuer competition. This move highlights ongoing institutional interest in Bitcoin ETFs despite broader ETF outflows, with Bitcoin ETFs making up 22.4% of US spot ETF assets under management in the quarter. The data reflects positions as of June 30, 2026, and may have shifted since then.
Wealth Enhancement's Bitcoin ETF holdings increased from $22M to $33M in Q2 2026. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 14, 2026 00:03 WIB: 16 of 50 major cryptocurrencies rose, 33 fell. Notable movers include XTZ at Rp5.809 (+4.33%, 82% Sell), THETA at Rp3.688 (-4.21%, 59% Buy), and NEO at Rp42.947 (-3.89%, 100% Buy).
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
